Nanobiotix (NBTX) announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating radioenhancer JNJ-1900 for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab. CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson (JNJ) company, under a global license agreement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Updates Voting Rights and Share Capital Information
- Nanobiotix to Unveil Future of Nanotherapeutics
- Nanobiotix Announces Key Share Acquisition Transactions
- Nanobiotix Executive Acquires Significant Share Volume, Signaling Confidence in Future Growth
- Nanobiotix Updates Share Capital and Voting Rights Information